The Ministry of Health and Prevention (MOHAP) in the United Arab Emirates (UAE) has granted BioCryst Pharmaceuticals marketing authorization for their oral medication ORLADEYO® (berotralstat) to help prevent frequent hereditary angioedema (HAE) attacks in patients 12 years and older. NewBridge Pharmaceuticals (NewBridge), which also covers the Gulf Cooperation Council (GCC) and Iraq is helping to support BioCryst’s commercialization efforts in the UAE and in MENA. Headquartered in Dubai, UAE, NewBridge Pharmaceuticals is a regional specialty company that aims to bridge the access gap between global pharma and biotech companies to commercialize U.S. FDA or EMA approved drugs that satisfy unmet medical needs for Middle East and North Africa (MENA) regions.
Read more here.